子宮癌放射療法時に於ける腟内癌細胞の位相差顕微鏡学的研究

1) Subjects of the present study are 49 cases with uterine cancer and one case with vaginal cancer, admitted to the Obstetrics and Gynecolgy Clinics of Okayama University Medical School during the period ranging from May 1956 to March 1957, and given irradiation therapy (Yagi-Takeda method); and observations have been carried out by the phase-contrast microscope in order to determine irradiation changes in vaginal cancer cells of these patients, using dried human serum solution as the sealing agent. 2) As the preliminary experiment, in cancer determinations on 79 patients admitted to our clinics during the period from Nov. 1955 to April 1956 and suspected of cancers, the positive percentage has proved to be 84.2 per cent, while the negative percentage to 94.8 per cent at the same time skill and invaluable experiences have been aquired for the observation of cancer cells as to ensure exact and infallible results. 3) Changes in cancer cells mainly consisted of vacuole formation, change in the nuclear membrane, loss of peripheral plasma, granule degeneration, hypertrophy, and change in nucleoles; and although a slight degeneration can be recognized already in the pre-irradiation stage, the degeneration becomes gradually more marked along with the treatment. In some, however, the degeneration disappears with hardly any change. Such changes occur in the period between 6 th and 9 th day after irradiation, and moreover, during the periods in which the amount of X-ray ranged from 1200 r to 2100 r, radium is not detectable. Furthermore, the degeneration disappears on the average of 25 th to 26 th day after irradiation and the average total dosage of X-ray at that time is 4745 r while that of radium is 3746 mgh. 4) It has been impossible to recongnize any distinct relationship between the rate of degeneration of cancer cells on one hand and the number of days required it to disappear, the tissue classification, especially the Nagase classification, age differences, differences in clinical stage and prognosis on the other.